

Konrad Talbot

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9359393/konrad-talbot-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

4,836
citations

26
h-index

41
g-index

41
ext. papers

5,594
ext. citations

8
avg, IF

4.92
L-index

#	Paper	IF	Citations
37	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. <i>Biochemical Pharmacology</i> , 2020 , 180, 114187	6	20
36	Insulin resistance and cognitive test performance in elderly adults: National health and nutrition examination survey (NHANES). <i>Journal of the Neurological Sciences</i> , 2018 , 388, 97-102	3.2	8
35	Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS. <i>American Journal of Human Genetics</i> , 2018 , 102, 1169-1184	11	73
34	Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia. <i>Molecular Neurobiology</i> , 2017 , 54, 1699-1709	6.2	14
33	Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , 2017 , 288, 176-186	5.7	27
32	Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes. <i>Neuropsychopharmacology</i> , 2017 , 42, 1349-1360	8.7	14
31	Gene expression elucidates functional impact of polygenic risk for schizophrenia. <i>Nature Neuroscience</i> , 2016 , 19, 1442-1453	25.5	622
30	Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia. <i>Molecular Psychiatry</i> , 2015 , 20, 1091-100	15.1	47
29	Oxidative stress reduces levels of dysbindin-1A via its PEST domain. <i>Neurochemistry International</i> , 2014 , 79, 65-9	4.4	4
28	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. <i>Neurodegenerative Disease Management</i> , 2014 , 4, 31-40	2.8	59
27	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S12-25	1.2	87
26	Mutations in the BLOC-1 subunits dysbindin and muted generate divergent and dosage-dependent phenotypes. <i>Journal of Biological Chemistry</i> , 2014 , 289, 14291-300	5.4	26
25	Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning. <i>Hippocampus</i> , 2014 , 24, 204-13	3.5	24
24	Mechanical ventilation triggers hippocampal apoptosis by vagal and dopaminergic pathways. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 693-702	10.2	50
23	Measuring cell-type specific differential methylation in human brain tissue. <i>Genome Biology</i> , 2013 , 14, R94	18.3	78
22	MeCP2 regulates the synaptic expression of a Dysbindin-BLOC-1 network component in mouse brain and human induced pluripotent stem cell-derived neurons. <i>PLoS ONE</i> , 2013 , 8, e65069	3.7	34
21	Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. <i>Hippocampus</i> , 2012 , 22, 230-40	3.5	64

20	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1339-53	15.9	567
19	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1316-38	15.9	1101
18	The schizophrenia susceptibility factor dysbindin and its associated complex sort cargoes from cell bodies to the synapse. <i>Molecular Biology of the Cell</i> , 2011 , 22, 4854-67	3.5	55
17	Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, E962-70	11.5	83
16	Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. <i>PLoS ONE</i> , 2011 , 6, e16886	3.7	60
15	EHD1 is a synaptic protein that modulates exocytosis through binding to snapin. <i>Molecular and Cellular Neurosciences</i> , 2010 , 45, 418-29	4.8	15
14	The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. <i>Progress in Brain Research</i> , 2009 , 179, 87-94	2.9	55
13	Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. <i>Human Molecular Genetics</i> , 2009 , 18, 3851-63	5.6	100
12	Low sociability is associated with reduced size of the corpus callosum in the BALB/cJ inbred mouse strain. <i>Brain Research</i> , 2008 , 1230, 211-7	3.7	58
11	Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. <i>American Journal of Pathology</i> , 2008 , 173, 1488-95	5.8	136
10	Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. <i>Human Molecular Genetics</i> , 2006 , 15, 3041-54	5.6	134
9	Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. <i>Nature Medicine</i> , 2006 , 12, 824-8	50.5	479
8	Neurodevelopment, neuroplasticity, and new genes for schizophrenia. <i>Progress in Brain Research</i> , 2005 , 147, 319-45	2.9	100
7	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1353-1363	15.9	345
6	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1353-63	15.9	154
5	A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. <i>Neurochemistry International</i> , 2000 , 37, 17-31	4.4	55
4	Phospholipase pathway in Alzheimer's disease brains: decrease in Galphai in dorsolateral prefrontal cortex. <i>Molecular Brain Research</i> , 1999 , 66, 188-90		8
3	Feline islands of Calleja complex: I. Cytoarchitectural organization and comparative anatomy. <i>Journal of Comparative Neurology</i> , 1988 , 275, 553-79	3.4	18

- 2 Feline islands of Calleja complex: II. Cholinergic and cholinesterasic features. *Journal of Comparative Neurology*, **1988**, 275, 580-603 3-4 27
- 1 Evidence that efferents from the basolateral amygdala innervate the dorsolateral neostriatum in rats. *Neuroscience Letters*, **1984**, 44, 71-5 3-3 23